PMID- 25437301
OWN - NLM
STAT- MEDLINE
DCOM- 20160208
LR  - 20150519
IS  - 1546-4156 (Electronic)
IS  - 0893-0341 (Linking)
VI  - 29
IP  - 2
DP  - 2015 Apr-Jun
TI  - A 24-Week, Open-Label Extension Study to Investigate the Long-term Safety, 
      Tolerability, and Efficacy of 13.3 mg/24 h Rivastigmine Patch in Patients With 
      Severe Alzheimer Disease.
PG  - 110-6
LID - 10.1097/WAD.0000000000000073 [doi]
AB  - The long-term safety, tolerability, and efficacy of high-dose 13.3 mg/24 h 
      rivastigmine patch in severe Alzheimer disease was evaluated in a 24-week, 
      open-label extension to the double-blind ACTION study. Safety and tolerability, 
      and efficacy on the Alzheimer's Disease Cooperative Study-Activities of Daily 
      Living scale-Severe Impairment Version (ADCS-ADL-SIV), Severe Impairment Battery 
      (SIB), and ADCS-Clinical Global Impression of Change (ADCS-CGIC) were assessed. 
      Overall, 197 patients continued on 13.3 mg/24 h patch; 199 uptitrated from 4.6 
      mg/24 h to 13.3 mg/24 h patch. The incidence of adverse events (AEs), serious AEs 
      and discontinuations due to AEs was similar in patients who continued on, and 
      patients who uptitrated to, 13.3 mg/24 h patch (AEs: 57.9% and 59.8%; serious 
      AEs: 16.2% and 16.1%; discontinuations: 11.2% and 12.1%, respectively). Larger 
      mean changes from double-blind baseline were observed in patients uptitrated on 
      the ADCS-ADL-SIV (-4.6; SD=8.7) and SIB (-7.0; SD=16.6), than those who continued 
      on 13.3 mg/24 h patch (-3.9; SD=8.0 and -4.7; SD=16.8, respectively). ADCS-CGIC 
      scores were comparable. There were no clinically relevant between-group 
      differences in safety and tolerability. Greater decline was observed in patients 
      with delayed uptitration to high-dose 13.3 mg/24 h patch than patients who 
      continued on high-dose patch.
FAU - Farlow, Martin R
AU  - Farlow MR
AD  - *Department of Neurology, Indiana University School of Medicine, Indianapolis, IN 
      daggerDepartment of Neurology and Psychiatry, St Louis University School of Medicine, 
      St Louis, MO double daggerDivision of Neurology, Nova Southeastern University, Fort 
      Lauderdale, FL  section signNovartis Pharmaceuticals Corporation, East Hanover, NJ.
FAU - Grossberg, George T
AU  - Grossberg GT
FAU - Sadowsky, Carl H
AU  - Sadowsky CH
FAU - Meng, Xiangyi
AU  - Meng X
FAU - Velting, Drew M
AU  - Velting DM
LA  - eng
PT  - Clinical Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Alzheimer Dis Assoc Disord
JT  - Alzheimer disease and associated disorders
JID - 8704771
RN  - 0 (Cholinesterase Inhibitors)
RN  - PKI06M3IW0 (Rivastigmine)
SB  - IM
MH  - Accidental Falls
MH  - Activities of Daily Living
MH  - Aged
MH  - Aged, 80 and over
MH  - Alzheimer Disease/*drug therapy
MH  - Cholinesterase Inhibitors/*administration & dosage/therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Longitudinal Studies
MH  - Male
MH  - Neuropsychological Tests
MH  - Prospective Studies
MH  - Rivastigmine/*administration & dosage/therapeutic use
MH  - Severity of Illness Index
MH  - Transdermal Patch
MH  - Treatment Outcome
MH  - Urinary Tract Infections/chemically induced
MH  - Weight Loss
EDAT- 2014/12/02 06:00
MHDA- 2016/02/09 06:00
CRDT- 2014/12/02 06:00
PHST- 2014/12/02 06:00 [entrez]
PHST- 2014/12/02 06:00 [pubmed]
PHST- 2016/02/09 06:00 [medline]
AID - 10.1097/WAD.0000000000000073 [doi]
PST - ppublish
SO  - Alzheimer Dis Assoc Disord. 2015 Apr-Jun;29(2):110-6. doi: 
      10.1097/WAD.0000000000000073.